A5081806198- Cannabis and Cannabinoid Research
- Neuroscience and Neuropharmacology Research
- Neurotransmitter Receptor Influence on Behavior
- Treatment of Major Depression
- Tryptophan and brain disorders
- Schizophrenia research and treatment
- Functional Brain Connectivity Studies
- Bipolar Disorder and Treatment
- Psychedelics and Drug Studies
- Forensic Toxicology and Drug Analysis
- Memory and Neural Mechanisms
- Sleep and Wakefulness Research
- Prenatal Substance Exposure Effects
- Chemical synthesis and alkaloids
- Substance Abuse Treatment and Outcomes
- Formal Methods in Verification
- Neuroscience of respiration and sleep
- Advanced MRI Techniques and Applications
- Homelessness and Social Issues
- Mental Health Research Topics
- Diet and metabolism studies
- Receptor Mechanisms and Signaling
- Obsessive-Compulsive Spectrum Disorders
- Medical Imaging Techniques and Applications
- Amino Acid Enzymes and Metabolism
Yale University
2016-2025
VA Connecticut Healthcare System
2016-2025
Connecticut Mental Health Center
2014-2024
Queen's University
2024
Singapore General Hospital
2022
National Center for PTSD
2020-2021
United States Department of Veterans Affairs
2000-2020
Indian Institute of Science Bangalore
2005-2016
Veterans Health Administration
2012
University of New Haven
2010
<h3>Importance</h3> Multiple lines of evidence suggest a deficit in dopamine release the prefrontal cortex (PFC) schizophrenia. Despite prevalence concept cortical hypodopaminergia schizophrenia, vivo imaging PFC has not been possible until now, when validity using positron emission tomographic D2/3 radiotracer carbon 11–labeled FLB457 combination with amphetamine paradigm was clearly established. <h3>Objectives</h3> To (1) test amphetamine-induced dorsolateral (DLPFC) drug-free or...
Abstract Twenty-four hours after administration, ketamine exerts rapid and robust antidepressant effects that are thought to be mediated by activation of the mechanistic target rapamycin complex 1 (mTORC1). To test this hypothesis, depressed patients were pretreated with rapamycin, an mTORC1 inhibitor, prior receiving ketamine. Twenty suffering a major depressive episode randomized pretreatment oral (6 mg) or placebo 2 h intravenous administration 0.5 mg/kg in double-blind cross-over design...
Background: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects from just one or two doses. However, methodological limitations (e.g., placebo-control, blinding) limit interpretability of the existing literature. Methods: In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with moderate to severe major depressive disorder were administered placebo ( n = 19) followed by...
Abstract Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). However, the mechanisms underlying its often persisting beneficial effects remain unclear. Observational research suggests improvements in psychological flexibility may mediate effects. no psychedelic trials to date substantiated this finding clinical sample. In an exploratory...